
|Articles|June 9, 2022
Daily OTC Pearl: Famotidine (Pepcid)
Author(s)Saro Arakelians, PharmD
Pepcid is indicated in adult and pediatric patients 40 kg and above for the treatment of active duodenal ulcer active gastric ulcer.
Advertisement
Medication Pearl of the Day: Famotidine (Pepcid)
Indication: Pepcid is a histamine-2 (H2) receptor antagonist indicated in adult and pediatric patients 40 kg and above for the treatment of active duodenal ulcer active gastric ulcer.
Insight:
- Dosing: May vary from 20 mg to 40 mg depending on the indication.
- Dosage forms: Tablets 20 mg and 40 mg.
- Adverse events: The most common adverse reactions are headache, dizziness, constipation, and diarrhea.
- Mechanism of action: Famotidine is a competitive inhibitor of H2 receptors. The primary clinically important pharmacologic activity of famotidine is inhibition of gastric secretion. Both the acid concentration and volume of gastric secretion are suppressed by famotidine, while changes in pepsin secretion are proportional to volume output.
Source:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Emerging Biomarkers Open New Frontiers in Lung Cancer Therapy
2
Dato-DXd Doubles Response Rates and Extends Survival in First-Line Metastatic TNBC
3
Targeted α-Particle Radioligand Therapy Shows Promising Activity, Low Toxicity in SSTR2-Positive Neuroendocrine Tumors
4
Weekly Paclitaxel May Hold the Key to Pembrolizumab’s Success in Platinum-Resistance Ovarian Cancer
5